HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Regulus Therapeutics Inc. (RGLS)
0.8788  -0.0113  (-1.27%) 06-21 03:52
Open: 0.8827 High: 0.9389
Pre.close: 0.8901 Low: 0.8706
Volume: 2,398,609 Ave vol: 2,805,677
52w High: 2.32 52w Low: 0.42
MA(50): 0.992 MA(200): 1.295
EPS: -0.338 P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.regulusrx.com
Market Cap (M): 66
Shares Out (M): 75
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Technical analysis
Overall: Underperform
MA: Bearish MACD: Bearish
KDJ: Bearish RSI: Bearish
Target 1: 1.44 Target 2: 1.73
Resist 1: 1.24 Resist 2: 1.48
Support 1: 0.84 Support 2: 0.70
Company key metrics
Revenue per Share: 0.2861
Net Income per Share: -0.4497
Cash per Share: 0.8888
Book Value per Share: 0.7441
Price to Sales: 4.8589
Price to Book Value: 1.8681
Earnings Yield: -0.3235
Dividend Yield: 0
Debt to Equity: 0
Debt to Assets: 0.3079
Financial analysis
Price to Book Value: Outperform
Return on Assets: Underperform
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Neutral
Stock Charts

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.